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1  | INTRODUC TION
The present document is a second contribution collecting the rec-
ommendations of an expert panel of transplant hepatologists ap-
pointed by the Italian Association for the Study of the Liver (AISF) 
concerning the management of some of the most common aspects 
of liver transplantation (LT). The method adopted to produce these 
recommendations involved the following steps: the six current 
members of the AISF Permanent Liver Transplant Commission 
(CPT) and one previous AISF CPT member jointly selected six top-
ics of major interest. One concerns the interaction between hepa-
tologists and transplant centres: how can the referral of candidates 
for LT be improved? The second topic concerns the management of 
difficult candidates for LT. The third relates to nutrition before and 
after transplantation. The fourth aimed to provide an update on liv-
ing donor LT, and its prospects. The fifth focuses on hepatocellular 
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Abstract
The present document is a second contribution collecting the recommendations of 
an expert panel of transplant hepatologists appointed by the Italian Association for 
the Study of the Liver (AISF) concerning the management of certain aspects of liver 
transplantation, including: the issue of prompt referral; the management of difficult 
candidates; malnutrition; living related liver transplants; hepatocellular carcinoma; 
and the role of direct acting antiviral agents before and after transplantation. The 
statements on each topic were approved by participants at the AISF Transplant 
Hepatology	Expert	Meeting	organized	by	the	Permanent	Liver	Transplant	Commission	
in	Mondello	on	12-	13	May	2017.	They	are	graded	according	to	the	GRADE	grading	
system.
K E Y W O R D S
end stage liver disease management, hepatocellular carcinoma, patient referral, transplant 
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carcinoma (HCC) and LT: is it time to expand the criteria adopted 
in Italy? The sixth topic of interest concerns how to deal with the 
failure of DAA treatment before and after LT.
As in the preparation of a previous position paper, the AISF CPT 
members appointed a working group for each of these topics, and 
one of the six AISF CPT members each chaired one of these groups 
of experts. A total of 49 transplant hepatologists (experts), identi-
fied on the grounds of their competence, role, expertise and publi-
cations/research in the field of end- stage liver disease and LT, were 
invited to join the working groups. The composition of the six groups 
is given in the Appendix. The chairman of each group selected the 
relevant clinical questions, relating both to clinical practice and to 
controversial issues.1
2  | INTER AC TION BET WEEN 
HEPATOLOGISTS AND TR ANSPL ANT 
CENTRES:  HOW C AN THE REFERR AL OF 
C ANDIDATES FOR LT BE IMPROVED?
End- stage liver disease (ESLD) is an increasingly common cause of 
death	worldwide.	In	the	USA,	the	years	of	life	lost	before	the	age	of	
75	because	of	ESLD	has	 risen	 from	164.1	per	100	000	 in	2000	to	
190.3 in 2015, exceeding the life years lost because of cerebrovascu-
lar	disease	(161.0),	colorectal	cancer	(123.3)	and	HIV	(50.4).2 LT is the 
best treatment for selected patients with ESLD, including those with 
decompensated cirrhosis and HCC. There are several barriers, how-
ever, that make it difficult for potentially eligible patients with ESLD 
to access LT at various stages. The obstacles may relate to: (a) referral 
to a LT centre for hospitalized cases or outpatients, by primary care 
physicians or specialists; (b) screening activities conducted by LT cen-
tres to confirm a patient’s eligibility for LT, and exclude contraindica-
tions; (c) patient listing, and patient management to enable them to 
survive while on the waiting list; and (d) organ allocation.
All patients with ESLD who are potentially eligible for LT should 
have equal access to waiting lists according to principles of equity, 
justice, and consistently managed within each centre, according to 
transparency. Failure to refer patients to LT centres, or delaying their 
referral, and/or excessively selective screening practices at LT cen-
tres are possible reasons why potentially eligible LT candidates with 
ESLD have limited access to waiting lists. Although the estimates are 
only approximate ( because of methodological bias), there is published 
evidence of such omitted referrals and low rates of ESLD patients on 
waiting listing.3-12 Data on the prevalence of referrals to LT centres 
coming too late are scarce, and limited to patients with HCC.13 To 
avoid their excessively late referral, it is strongly recommended that 
the initial referral of potentially eligible ESLD patients to LT centres 
be optimally timed, i.e, before the disease reaches the stage when the 
patient’s listing for LT is actually indicated.14-16 This is partly because 
it takes time for such potential candidates for LT to undergo the nec-
essary multidisciplinary assessment before they can join the waiting 
list, and partly because the condition of some patients with ESLD may 
deteriorate rapidly, soon preventing them from accessing a LT. Few 
data are available on LT centres’ selection procedures for including 
candidates with ESLD on their LT waiting lists.10,13
2.1 | Question 1
Is there any evidence of inadequacies in the referral of ESLD pa-
tients who are potential candidates for LT and/or their access to 
waiting lists (worldwide vs Italy)?
2.1.1 | Statement
Referral is defined as the first contact with a transplant hepatolo-
gist. In Italy there is a low referral rate for ESLD patients, but re-
ferral patterns and LT waiting list accessibility to potentially eligible 
candidates with ESLD should be monitored, clarifying the causes of 
suboptimal access and taking action to improve it. (B, I)
2.1.2 | Comment
Although the estimates are scarcely accurate because of methodo-
logical	bias,	 evidence	published	 in	 the	USA	and	France	points	 to	
a low rate of access to LT waiting lists for potentially eligible can-
didates with ESLD. In particular, retrospective studies comparing 
the number of adult patients with ESLD actually listed with the 
number potentially eligible, or with the number of deaths among 
such potentially eligible candidates for LT, showed they accounted 
for relatively small proportions of the patients listed from 1999 
to 2014, in the range of 5%- 29%.3-6,9 It is also clear from retro-
spective	 studies	 performed	 in	 the	 USA,	 France	 and	 Germany,	
especially those focusing on alcoholic- related liver diseases, and 
enrolling patients from 2002 to 2013, that the small proportions 
of patients with ESLD on waiting lists was largely because of the 
low rate of referral of such potential candidates for LT to transplant 
Key points
• Patient eligible for liver transplantation should be re-
ferred to a transplant hepatologist, evaluated and man-
aged with transparency and consistency among 
different centres.
• Patients awaiting liver transplantation may have extra 
hepatic comorbidities and impaired nutritional status, 
therefore a multidisciplinary approach aimed to imple-
ment candidate selection, balanced calorie intake, phys-
ical activity and behavioural changes, is needed.
• Living donor liver transplant is challenging because of 
donor and recipient issues and requires professionals 
working in multidisciplinary team.
• Indications to liver transplantation are changing with de-
creasing burden of HCV-related end stage liver disease, 
and HCC will become the leading indication.
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centres.7,8,10-12	No	published	data	are	available	on	the	rates	of	ar-
rival on the waiting list, referral patterns, or LT centre selection 
procedures in Italy.
Based on unpublished data drawn from several countries’ 
death and transplant registries in 2014, it was estimated that the 
rate of access to LT waiting lists for adults with ESLD potentially 
eligible	for	LT	was	similar	in	Italy	to	the	situation	in	the	USA,	but	
1.7	times	lower	than	in	Spain.17-22 Thus, there is a need to monitor 
the referral patterns and the access to the waiting lists in Italy. This 
could be achieved in the future at two levels. Firstly, by compar-
ing disease- specific death registries of potential LT candidates and 
detailed reports of all the LT candidates referred to the Italian liver 
transplant centres. Secondly, the outcomes of all the referred pa-
tients (listed or not listed, including reasons for not listing) should 
be monitored overtime and compared among different centres.
2.2 | Question 2
Do patients with or without HCC have the same chances of being 
referred to a transplant centre and accessing the waiting lists for LT 
(worldwide vs Italy)?
2.2.1 | Statement
In Italy, indirect data suggest a difference in the referral of patients 
with or without HCC, and their access to a waiting list for LT, in fa-
vour of patients with HCC. We should measure the accessibility 
of LT for potentially eligible cirrhotic candidates with and without 
HCC, to clarify the reasons behind any suboptimal access for such 
patients, and take action to improve it. (B, I)
2.2.2 | Comment
In	the	USA	there	is	evidence	of	a	marked	difference	in	the	numbers	
of cirrhotic patients with vs without HCC accessing a waiting list for 
LT.4	A	retrospective	study	using	two	large	databases	in	the	USA,	and	
enrolling more than 84 000 patients, showed that 29% of patients 
with HCC potentially eligible for LT, but only 11.9% of patients with 
stage	4	cirrhosis	(ascites),	and	12.6%	of	those	with	stage	5	cirrhosis	
(ascites and variceal bleeding) were placed on the waiting list over 
a 2 year period. Among patients divided by stage of cirrhosis, those 
with HCC were significantly more likely to be listed for LT, with ad-
justed	 sub-	hazard	 ratios	 ranging	 from	1.7	 (for	patients	with	 stage	
5 cirrhosis with vs without HCC) to 5.8 (for patients with stage 1 
cirrhosis with vs without HCC). This disproportionate access to LT 
waiting lists in favour of patients with HCC is likely to be even more 
pronounced in Italy, where the percentage of transplants performed 
in	patients	with	HCC	is	almost	twice	as	high	as	in	the	USA.20,23
2.3 | Question 3
Is there a need to improve the referral of candidates for LT and in 
which particular aspects?
2.3.1 | Statement
Every effort should be made to increase the rate of referral to a 
transplant centre and access to a transplant program, because all 
potentially eligible candidates with ESLD should have the same 
chances of being assessed for a LT, and should receive optimal pre-
transplant treatment. (B, I)
2.3.2 | Comment
All potential candidates for LT with ESLD should have the same 
chances of being assessed for a transplant according to principles of 
justice and equity with a transparent evaluation, consistent among the 
different	 centres.	 Recent	 retrospective	 data	 from	 the	USA	 suggest	
that being listed per se, even for patients who never receive a trans-
plant, affords a survival benefit: the adjusted survival from the diagno-
sis of ESLD in patients with decompensated cirrhosis and/or HCC was 
significantly longer for those listed for LT but not transplanted than in 
potentially eligible candidates who were never listed, in the absence of 
different medical comorbidities between the two groups.6
2.4 | Question 4
When is the best time to refer potential candidates for LT with se-
vere acute hepatitis, acute liver failure (ALF) or acute on chronic liver 
failure (ACLF)?
2.4.1 | Statement
All patients with severe acute hepatitis, ALF or ACLF should be referred 
immediately to a liver centre with access to a transplant program. (B, I)
2.4.2 | Comment
A retrospective study comparing the number of adult patients with 
ALF placed on a waiting list for LT with the number of deaths among 
ALF patients potentially eligible for LT showed a low rate of listing 
(25%)	 for	patients	enrolled	 in	 the	USA	 from	1999	 to	2006.9 Since 
late referral is probably the main reason for such low listing rates for 
such patients, it is important to refer them to a liver centre as soon 
as possible, even those with a diagnosis of severe acute hepatitis (i.e, 
without encephalopathy). The same early referral strategy should be 
applied to potentially eligible candidates with ACLF too.
2.5 | Question 5
When is the best time to refer patients with HCC who are candidates 
for a LT?
2.5.1 | Statement
All patients with a suspected or confirmed diagnosis of HCC should 
be	 promptly	 assessed	 by	 a	 multidisciplinary	 team	 (MDT)	 that	 in-
cludes a transplant hepatologist. (C, I)
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2.5.2 | Comment
Liver transplantation is indicated in patients with HCC meeting 
the maximum criteria for transplant eligibility, i.e, no evidence of 
macrovascular invasion or metastasis, and a limited tumour size. 
The	 Milan	 criteria	 are	 the	 most	 generally	 accepted,	 but	 some	
centres	use	expanded	criteria	for	tumour	size	(San	Francisco,	Up	
to seven, etc.). Locoregional treatments may also enable tumours 
initially exceeding the size restrictions to be downstaged to meet 
these criteria. It is therefore very important for patients with 
newly	diagnosed	HCC	to	be	promptly	discussed	by	a	MDT	that	
includes a transplant hepatologist, a liver and transplant sur-
geon, a liver radiologist, an oncologist and a specialist nurse in 
HCC. This also applies to patients with very small or even only 
suspected HCC because LT centres may vary in their approach 
and the criteria they adopt.15 Thus, all patients with HCCs and 
without obvious absolute contra- indication to transplant should 
be	 referred	 to	 a	MDT	 in	 a	 specialized	 centre	with	 access	 to	 all	
treatments for HCC, including transplantation to reduce the 
rate of late referrals for transplantation and the risk of biases in 
treatments.
2.6 | Question 6
When is the best time to refer patients with cirrhosis without HCC 
for assessment for LT?
2.6.1 | Statement
Patients with cirrhosis unrelated to any cholestatic chronic liver dis-
ease and without obvious absolute contra- indication to transplant 
should be referred to a transplant hepatologist at their first decom-
pensating	event,	when	their	MELD	score	 is	≥10	and/or	 their	Child	
Pugh	score	is	≥7.	(B, I)
Patients with cirrhosis because of a chronic cholestatic liver dis-
ease and without obvious absolute contra- indication to transplant 
should be referred to a transplant hepatologist at their first decom-
pensating	event	and/or	when	their	Mayo	score	 is	≥6.5	for	primary	
biliary	cholangitis,	or	≥1	for	primary	sclerosing	cholangitis.	A	domi-
nant biliary stricture, severe metabolic bone disease and symptoms 
associated with a poor quality of life (QoL), such as intractable pru-
ritus, recurrent cholangitis or xanthomatous neuropathy should also 
be independent reasons for prompt referral. (B, I)
2.6.2 | Comment
Referral to a transplant hepatologist is strongly recommended when 
a patient with cirrhosis is still well enough to be assessed and listed, 
but ill enough to have a reduced survival and/or poor QoL. Given 
the time it takes to complete an assessment before a patient can 
be listed for LT, and the risk of some patients’ conditions deterio-
rating rapidly to the point where a transplant is no longer feasible, 
the optimal timing for initial referral to a transplant hepatologist of 
patients with cirrhosis potentially eligible for LT should be before 
their disease reaches the stage when their listing for a transplant is 
actually indicated.14-16 In the case of non- cholestatic cirrhosis, pa-
tients	should	be	referred	when	their	MELD	score	is	≥10,	even	in	the	
absence	of	MELD	exceptions,	while	 the	minimum	MELD	score	 for	
listing	a	patient	 is	15.	Similarly,	 it	has	been	suggested	that	a	Mayo	
risk score predicting more than 10% mortality at 1 year without 
LT should prompt referral for patients with cholestatic disease. 
Recurrent cholangitis, intractable pruritus, severe metabolic bone 
disease, and xanthomatous neuropathy should also prompt referral 
for patients with cholestatic diseases.15
2.7 | Question 7
Can we design a study to investigate how to improve the referral for 
assessment of potential candidates for LT?
2.7.1 | Statement
The design of a study aiming to improve the referral of patients with 
ESLD potentially eligible for LT to transplant centres should envisage:
1. A baseline survey addressed to transplant hepatologists at all 
Italian LT centres to obtain details of the number of LT can-
didates referred and their outcomes (listed or not listed, in-
cluding reasons for not listing) in the last 2 years.
2. An intervention to improve cooperation with referring physicians 
by providing a simple web-based patient referral tool (a system of 
electronic referral, or eReferral for LT) and a regional network for 
hepatic diseases based on educational activities promoted by the 
tertiary transplant centre in conjunction with the secondary cen-
tres and with outreach clinics to increase awareness, improve 
communication and optimize patient referrals at a more appropri-
ate time and an earlier stage for LT.
3. Repetition of the same survey 1 year after the intervention. 
 (C, IIb)
2.7.2 | Comment
A study conducted in Germany demonstrated that referral pat-
terns can be substantially improved by intervention using an inter-
disciplinary approach, based especially on the activity of dedicated 
transplant hepatologists, and with the involvement of referring 
physicians and patient organizations at meetings and symposia.10 
The “eReferral (electronic referral) web- based system for LT” is a 
simple tool for referring patients with ESLD who are non- urgent 
candidates for LT (excluding patients with severe acute hepatitis, 
ALF or ACLF). It was developed in Italy and initially used by three 
transplant centres in the Lazio Region. It will be tested for the 
purposes of changing referral and listing patterns over time. The 
eReferral website also enables patients’ first visit to be scheduled 
appropriately according to their urgency (based on recent clinical 
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data), and their comanagement by the transplant hepatologist and 
the referring physician, as well as providing educational links for 
the latter.
3  | THE “DIFFICULT C ANDIDATE” FOR LT
Liver transplantation technique has improved dramatically over 
the years. A successful outcome requires optimal patient selec-
tion and timing, so deciding which patients to list for LT remains 
a key issue that continues to generate debate and controversies. 
At present, there are few absolute contraindications to LT, and 
they generally refer to situations for which enough experience has 
been gained to establish that the transplanted patients’ outcome 
is not acceptable.14,24 It is important to emphasize, however, that 
the contraindications to LT are always changing, and they may also 
vary between different transplant centres, reflecting local exper-
tise.	Meanwhile,	progress	has	been	made	in	our	understanding	of	
pre- and post- LT physiology, and the introduction of newer, more 
effective immunosuppressants to prevent graft rejection has re-
sulted in increasing the 5- year patient and graft survival rates by 
>80%	in	Europe	and	the	USA.25,26 On the other hand, the trans-
plant community is currently facing a major organ shortage.27 This 
has put a great deal of pressure on organ allocation programs, and 
many patients become seriously ill or die while on the waiting list 
for LT.
Taking all these aspects into account, some patients have one 
or more clinical conditions that place them at the limit for safely in-
dicating LT: these are the so- called “difficult candidates” for LT. The 
purpose of this section is to explore several demographic and clinical 
conditions that identify these “difficult candidates,” then a panel of 
experts advances some recommendations to orient the decision- 
making process to apply in such cases.
3.1 | Question 1
Is there an age limit above which LT is contraindicated?
3.1.1 | Statement
Although there are no age limits for LT recipients, patients between 
65	and	70	years	old	should	be	carefully	assessed	in	terms	of	trans-
plant benefit because of the high prevalence of comorbidities in the 
more elderly. (A, I)
3.1.2 | Comment
Patients	over	the	age	of	60-	65	years	have	been	shown	to	have	lower	
1- and 5- year survival rates after LT than younger patients.28 Some 
transplant teams consider physiological age more important than 
chronological age, however,29,30 centres that have come to accept 
70	years	as	the	age	 limit	for	transplantation	have	reported	obtain-
ing good results with this policy.31 It is largely accepted that, when 
questions about a potential recipient’s age arise, they should be 
carefully discussed by the transplant team.
3.2 | Question 2
Which cardiovascular diseases negatively influence a patient’s eligi-
bility for LT?
3.2.1 | Statement
It is advisable to involve an expert cardiologist in assessing the car-
diac risk of candidates for LT. (C, IIb)
A basic physical examination, electrocardiography and echocar-
diography are required for all LT candidates. (A, I)
More	specific	cardiac	tests	and	a	systemic	vascular	assessment	
with Doppler ultrasound are recommended for LT candidates with 
a history of cardiovascular diseases and/or known risk factors (dia-
betes mellitus, hypertension, pre- existing coronary artery disease, 
dyslipidaemia,	age	>60	years).	(A, IIa)
Severe cardiac dysfunction or major electrophysiological abnor-
malities not amenable to medical or surgical treatment specifically 
contraindicate LT. (A, IIa)
Candidates with a systolic pulmonary arterial pressure 
>45 mm Hg on echocardiography should undergo right cardiac cath-
eterization. (A, I)
3.2.2 | Comment
Cardiac abnormalities relating to an abnormal systolic contractile 
response to stress, a diastolic dysfunction at rest, and several elec-
trophysiological anomalies have been demonstrated in patients with 
advanced cirrhosis, irrespective of the etiology of their liver disease. 
The condition is termed cirrhotic cardiomyopathy.32
Perioperative cardiovascular complications are a leading cause 
of morbidity and mortality after LT.33 While it is generally agreed 
that cardiac function warrants careful assessment in LT candidates, 
there is no standardized way to do so. Patients with multiple cardio-
vascular risk factors should first have a cardiopulmonary exercise 
test to identify any signs of coronary artery disease. The recom-
mended second- line tests in patients with tense ascites, sarcopenia 
and/or severe motility impairment whose target heart rate cannot 
be achieved during a standard exercise test, a pharmacological stress 
test14,24 or coronary artery assessment with contrast- enhanced 
computed tomography (CT) scan or cardiac magnetic resonance im-
aging	 (MRI),34 or coronary angiography.35 When clinically relevant 
coronary artery disease is identified, candidates can be reconsidered 
for LT following a successful bypass surgery or angioplasty, since 
survival after LT does not differ significantly between patients with 
and without obstructive coronary artery disease providing the for-
mer have been properly treated before LT.36
Liver transplantation should be considered with caution for 
patients with a left ventricular ejection fraction <55% on echo-
cardiography, taking into account any other cardiac abnormalities 
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contributing to the picture of cirrhotic cardiomyopathy.32 There 
are no clear recommendations against LT for patients with cardiac 
electrophysiological abnormalities because prolonged QT intervals, 
electromechanical dyssynchronies and chronotropic incontinence 
generally disappear after the transplant.32 In the event of major, se-
vere electrophysiological abnormalities not amenable to medical or 
surgical treatment, the risk/benefit ratio of LT should be assessed 
case by case with a cardiologist who has demonstrable expertise in 
the management of complex cardiac arrhythmias.
Portopulmonary hypertension (PPH) is defined as a mean pulmo-
nary	artery	pressure	 (MPAP)	>25	mm	Hg	at	rest,	a	pulmonary	vas-
cular resistance >240 dyn s cm−5, and a normal left atrial pressure 
(<15 mm Hg), measured by means of a right cardiac catheterization 
procedure.37 Identifying PPH and properly assessing its severity 
prior to LT is of paramount importance because it influences the 
clinical	outcome	after	LT:	 if	 the	MPAP	is	<35	mm	Hg,	the	outcome	
after	LT	is	good,	whereas	MPAP	values	between	35	and	50	mm	Hg,	
or >50 mm Hg are associated with post- LT mortality rates of 50% 
and 100% respectively.38 Pharmacological treatments such as epo-
prostenol (prostacyclin), or prostacyclin analogues (iloprost, tre-
prostinil), endothelin receptor antagonists, or phosphodiesterase 
inhibitor type 5 (sildenafil) have recently been used to treat PPH 
and found to improve pulmonary hemodynamics in some patients. 
Although LT has sometimes been performed in patients treated 
with these agents, the long- term results are still under evaluation.39 
There is a general agreement that patients with PPH who achieve a 
MPAP	≤35	mm	Hg	in	response	to	medical	therapy	with	the	above-	
mentioned drugs could be considered suitable for LT.14,40
3.3 | Question 3
What is the best way to establish a sufficient degree of respiratory 
function in LT candidates?
3.3.1 | Statements
Respiratory function should be assessed by means of: lung function 
tests, measuring the diffusion capacity of the lung for carbon mon-
oxide, arterial blood gas analysis, and a chest X- ray. If hepatopul-
monary syndrome (HPS) is suspected, further investigations are 
warranted. (A, I)
Hepatopulmonary syndrome can be an isolated indication for LT. 
Recipients with a PaO2	≤50	mm	Hg	and	no	reversibility	to	100%	oxy-
gen risk irreversible respiratory failure in the post- LT period, and are 
at high risk of perioperative mortality. (B, IIa)
3.3.2 | Comment
Hepatopulmonary syndrome is a liver- related respiratory complica-
tion	affecting	about	10%-	17%	of	patients	with	cirrhosis.	It	is	caused	
by abnormal intrapulmonary vascular dilations, mainly in the basal 
parts of the lung, which lead to hypoxaemia, and patients with 
HPS often need oxygen therapy. The diagnosis is established if an 
arterial blood gas sample taken from a seated patient reveals an 
alveolar- arterial oxygen gradient (AaO2)	 ≥15	 or	 ≥20	mm	Hg	 in	 pa-
tients	 over	 64	years	 old.	Other	 parameters	 previously	 used	 to	 di-
agnose HPS were: an AaO2 >20 mm Hg (regardless of age) and/or 
a pO2	<70	mm	Hg	with	the	patient	in	any	supine,	sitting	or	standing	
position.41 Intrapulmonary shunts are identified on transthoracic 
contrast- enhanced echocardiography,42 or a macro- aggregated al-
bumin	lung	perfusion	scan	([99m]Tc-	MAA).43
The severity of HPS is graded according to the level of hy-
poxaemia as: mild (PaO2	≥	80	mm	Hg),	 moderate	 (PaO2 <80 and 
≥60	mm	Hg),	 severe	 (PaO2	 <60	 and	 ≥50	mm	Hg)	 or	 very	 severe	
(PaO2 <50 mm Hg); very severe HPS is often associated with a 
PaO2 <300 mm Hg when the patient is given 100% oxygen.
42
Liver transplantation has been shown to reverse the syndrome 
and improve survival rates, even in severe cases. It is essential to 
assess the severity of HPS properly, however, because patients with 
a PaO2 < 50 mm Hg and no reversibility to 100% oxygen may risk ir-
reversible respiratory failure after LT and carry a high risk of periop-
erative mortality.44 It is also important to remember that it may be 
several months after LT before any improvement or reversibility of 
HPS becomes apparent.45
3.4 | Question 4
Which kidney diseases justify a combined liver- kidney transplant 
(LKT)?
3.4.1 | Statements
Patients with renal dysfunction require accurate pre- LT evaluation 
to establish the etiology and prognosis of their kidney disease. (A, I)
A hepatorenal syndrome (HRS) associated with acute kidney in-
jury (AKI), or type II HRS, is not an indication for combined LKT. (A, I)
For stage IV chronic kidney disease (CKD), chronic hemodialysis 
or	sustained	AKI	(≥6	weeks),	combined	LKT	is	an	option	that	should	
be discussed with nephrologists and surgeons. (B, IIb)
3.4.2 | Comment
The choice of a combined LKT is generally driven by concern over 
the chances of recovery of a patient’s renal function, and the higher 
patient mortality associated with renal function failing to recover 
after LT alone.46
The definition of AKI in patients with cirrhosis was recently re-
vised by a panel of experts for the International Ascites Club (ICA). 
AKI is now defined as an increase in serum creatinine of at least 
0.3 mg/dL within 48 hours, or a 50% (1.5- fold) increase from the 
baseline	within	7	days.47 Three stages of AKI have been identified 
on the basis of the increase in serum creatinine levels and the need 
for renal replacement therapy.47 The change made to the definition 
of AKI in patients with cirrhosis highlights the need to revise the cri-
teria for defining HRS type 1. The current criteria include a 2- week 
period over which serum creatinine should double to >2.5 mg/dL.48 
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Adopting the proposed new ICA algorithm to manage AKI in patients 
with cirrhosis, patients who have AKI stages 2 or 3, or AKI progress-
ing from its initial stage despite general therapeutic measures, and 
who meet all the other criteria for a diagnosis of HRS according to 
the previous definition, should receive vasoconstrictors and albu-
min irrespective of their final serum creatinine level.47 HRS type 
2 is characterized by moderate renal failure (serum creatinine 1.5- 
2.5 mg/dL) with a steady or slowly progressive course, and is typi-
cally associated with refractory ascites. The survival of patients with 
HRS type 2 is better than for patients with HRS type 1.48
Chronic kidney disease is defined as an estimated glomerular 
filtration	 rate	of	<60	mL/min,	 calculated	using	 the	Modification	of	
Diet	in	Renal	Disease	6	(MDRD6)	formula,	persisting	for	more	than	
3 months.49
It can be difficult to assess renal clearance in patients with cir-
rhosis, so testing the clearance of inulin or other exogenous markers 
might facilitate decision- making.50 When feasible, renal biopsy can 
help to detect any severe kidney disease, and establish whether it 
can be ameliorated after LT. Renal biopsy specimens demonstrating 
>30% glomerulosclerosis, or >30% fibrosis can be used to identify 
patients who require LKT.24
3.5 | Question 5
How can a history of non- hepatic cancer negatively affect a patient’s 
eligibility for LT?
3.5.1 | Statements
Liver transplantation candidates with a history of extra- hepatic tu-
mours should have received a curative treatment, and be tumour- 
free at the time of their assessment for listing them for LT. (A, I)
Recipients with a history of cured extra- hepatic malignancies 
can be considered for LT to a recurrence- free interval that depends 
on the type of tumour involved (Israel Penn International Transplant 
Tumor Registry). (B, I)
3.5.2 | Comment
Immunosuppressant treatment after LT is associated with a higher 
risk of recipients developing extra- hepatic malignancies,51 so it 
is strongly recommended that all candidates for LT be accurately 
screened for malignancies before they join the waiting list.
The issue regarding the eligibility for LT of patients with a 
history of extra- hepatic cancer is more complex. The success of 
oncological treatments depends on the type and spread of the 
neoplastic disease involved, and these factors crucially influence 
the prognosis. In this setting, it is therefore essential to identify 
the type of extra- hepatic tumour and the treatment a patient 
received. An expected outcome should be calculated, and suffi-
cient time should have elapsed to minimize the risk of recurrence. 
The Israel Penn International Transplant Tumor Registry (www.
ipittr.uc.edu/registry) is a large database of outcomes after LT in 
recipients with a variety of tumours that can be helpful in planning 
an appropriate strategy for LT candidates with a history of extra- 
hepatic malignancies.24 It is generally accepted that such patients 
are eligible for LT if the risk of tumour recurrence is estimated to 
be less than 10%. A 5- year recurrence- free interval is often re-
quired too, though this may vary considerably depending on the 
type of malignancy.14
It is still unclear whether LT recipients with a history of success-
fully treated extra- hepatic cancer should be assigned to a personal-
ized oncological surveillance program after LT.
3.6 | Question 6
Which psychiatric conditions and types of substance abuse could 
contraindicate LT?
3.6.1 | Statements
All LT candidates should undergo an accurate psychosocial evalua-
tion to assess their compliance and adherence to medical directives 
and the stability of their mental health before and after LT. (A, IIa)
Most	 psychiatric	 disorders	 make	 patients	 relatively	 unsuitable	
for LT, and warrant psychological and psychiatric assessment and 
monitoring before and after any transplant is undertaken. (B, IIb)
Repeated suicide attempts and active psychosis not controlled 
with pharmacological therapy in patients without social and family 
support, should be considered psychiatric disorders that absolutely 
contraindicate LT. (B, I)
Non-	therapeutic	 use	 of	 opioids	 or	 active	 and	 continuative	 co-
caine or synthetic drug abuse make LT absolutely contraindicated. 
(B, I)
3.6.2 | Comment
The main aspects to consider in the psychosocial evaluation of candi-
dates for LT include: evidence of compliance with medical directives; 
adequate support from capable caregivers; and absence of active 
psychiatric disorders liable to affect compliance or induce behaviour 
harmful to health.24 Patients with chronic hepatic encephalopathy 
should	undergo	neuropsychological	 testing,	brain	CT	scan	or	MRI,	
and electroencephalography to ascertain the reversibility of their 
neuropsychiatric conditions.14
Active drug or alcohol abuse, or the non- therapeutic use of opi-
oids, cocaine or synthetic drugs, are considered a contraindication 
to LT for numerous reasons, including the related risks of recidivism, 
non- compliance and graft injury.14
On the other hand, stably abstinent, methadone- maintained, 
opiate- dependent patients may be eligible for LT because they show 
low relapse rates. There is also no conclusive evidence to suggest 
that patients with ESLD being treated with methadone have worse 
outcomes.52 Whether patients who regularly use marijuana should 
be excluded from the waiting list for LT is debatable:53	In	a	US	survey	
conducted	at	102	adult	LT	centres,	46.7%	of	the	centres	considered	
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the daily consumption of marijuana an absolute contraindication, 
whereas 43% judged it a relative contraindication, and 10.3% con-
sidered it irrelevant.54 Although it was suggested that patients who 
use compared to those who do not use marijuana are less likely to 
be transplanted, there was no significant difference in post- LT sur-
vival between the two groups.55 Furthermore, unlike illicit drug use, 
marijuana use was not associated with worse outcomes on the LT 
waitlist.56
In addition to addressing psychiatric and substance abuse issues, 
the evaluation process should include assessing the patient’s social 
support network. Caring for a transplant recipient involves frequent 
medical check- ups and tests, so a caregiver needs to be identified 
who can manage the patient’s transport and other logistic require-
ments, especially in the early period after LT.24
4  | THE MANAGEMENT OF NUTRITION 
BEFORE AND AF TER TR ANSPL ANTATION
Malnutrition,	sarcopenia	and	obesity	are	common	comorbidities	as-
sociated with poor pre- and post- transplant outcomes and a heavy 
burden on healthcare resources.
Malnutrition (or undernutrition) is a disorder resulting from an in-
adequate intake or uptake of nutrients that leads to an altered body 
composition (a reduction in fat free mass) and body cell mass, di-
minished physical and mental functioning, and a worse clinical out-
come in the event of disease.57 Sarcopenia is a separate syndrome 
characterized by a progressive, generalized loss of skeletal muscle 
mass, strength and function (performance) with a consequent risk 
of adverse outcomes.57 Obesity is an abnormal or excessive fat ac-
cumulation that may impair health.57 These different conditions may 
coexist in the same patient with cirrhosis. An association between 
malnutrition and sarcopenia can be expected, but obese patients can 
be sarcopenic too, or even malnourished, because of an imbalance 
between their energy intake and expenditure, and to the quality of 
their nutrient intake.57 As nutritional disorders are potentially mod-
ifiable, transplant physicians have recently been paying more atten-
tion to recognizing them, understanding their impact on transplant 
patient mortality and morbidity, and developing appropriate treat-
ment strategies.
4.1 | Question 1
Is nutritional status clinically relevant in patients with cirrhosis 
awaiting LT?
4.1.1 | Statements
Sarcopenia is an independent risk factor for mortality both before 
and after LT. (A)
Malnutrition is associated with a higher risk of poor outcomes. (B)
Moderate-severe obesity (body mass index—BMI > 35), combined 
with comorbidities, such as diabetes or cardiovascular risk factors, 
is associated with a higher risk of morbidity and mortality. The risk 
increases with the grade of obesity. (A)
Nutritional disorders should not per se be considered absolute 
contraindications to LT. They are conditions that need to be recog-
nized, however, in order to plan nutritional intervention, and they 
contribute to an individual’s risk profile. (C, I)
Nutritional assessments should be performed in all patients await-
ing LT. (A, I)
4.1.2 | Comments
The prevalence of malnutrition, sarcopenia and obesity is consist-
ently high in studies on patients with cirrhosis on the waiting list 
for LT, albeit with a broad variability because of different diagnostic 
methods and criteria being used. Malnutrition develops in 20%- 90% 
of patients with cirrhosis,58 and sarcopenia	 in	40%-	70%	of	cases.59 
The impact of obesity has been increasing in recent decades, reach-
ing a prevalence of almost 35% among patients awaiting LT in the 
USA.60 Sarcopenic obesity is identified in about 20% of patients with 
cirrhosis.61
Nutritional	disorders	clearly	affect	the	prognosis	of	patients	with	
cirrhosis and/or awaiting LT, even though the available studies reveal 
several flaws relating to their design (often retrospective and/or on 
small samples), methods, diagnostic criteria and prognostic cut- offs.
Malnutrition (undernutrition) is associated with a higher risk of 
in- hospital mortality and clinical complications in patients with 
cirrhosis.62,63 In the transplantation setting, it has been associated 
with increased post- transplant mortality and morbidity rates, and 
especially a higher incidence of bacterial and fungal infections, lon-
ger	stays	in	the	intensive	care	unit	(ICU)	and	in	hospital,	and	higher	
healthcare costs.64-66	 A	 BMI	 <18.5,	 as	 a	 simple,	 rough	 indicator	
of malnutrition, also identifies patients at higher risk of increased 
post-	transplant	mortality,	as	emerged	from	an	analysis	of	the	UNOS	
database.67
Sarcopenia is objectively measureable and represents the nutri-
tional variable most strongly associated with a patient’s prognosis 
after LT. Loss of muscle mass has been found to independently pre-
dict pre- and post- transplant mortality and morbidity, related mainly 
to a higher incidence of infections.64,68,69 Interestingly, the predic-
tion of mortality after LT appears to be more accurate in patients 
with	 low	MELD	 scores	 (<15),	 and	 adding	 sarcopenia	 to	 the	MELD	
variables	 (MELD-	sarcopenia)	 improves	 the	 prognostic	 capacity	 of	
MELD	alone	in	this	group	of	patients.68	This	explains	why	the	ICU	
and hospital stays are longer, and the related costs are higher for 
patients with sarcopenia.64
Patients with severe obesity (BMI > 40) appear to be at higher risk 
of post- transplant mortality and morbidity, as well as longer hospital 
stays and higher costs,60,67,70 but this picture has not always been 
confirmed.71 Moderate obesity (BMI 35-40) carries an adverse impact 
on post- transplant outcomes when associated with comorbidities, 
such as diabetes and cardiovascular disease.72 The prognosis after LT 
is not affected in patients who are overweight (BMI 25-30) or mildly 
obese (BMI 30-35).60,67,70
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4.2 | Question 2
How can we assess nutritional disorders in patients with cirrhosis 
awaiting LT?
4.2.1 | Statements
There is no standardized diagnostic algorithm for assessing the nu-
tritional status of patients with cirrhosis awaiting LT transplantation. 
A pragmatic strategy applicable in daily clinical practice should be 
based on a compromise between simplicity, reproducibility, and ac-
curacy. (C, I)
Since sarcopenia is the strongest predictor of pre- and post- 
transplant outcomes, it should be assessed in all patients awaiting 
LT. (A, I)
Muscle mass should preferably be quantified by means of cross- 
sectional imaging studies, using the L3 skeletal muscle index (L3 
SMI),	 for	 instance,	or	 the	psoas	muscle	 area	 (PMA),	 given	 that	CT	
scans	or	MRI	are	commonly	used	in	the	assessment	of	patients	for	
listing purposes. These measurements also correlate strongly with 
whole body muscle area, even in the case of fluid overload or obe-
sity. (A, I)
Measuring	gait	speed	and	hand-	grip	strength	could	be	useful	to	
assess muscle strength and function as an indicator of physical frailty, 
and for longitudinal reassessment purposes. (B, I)
4.2.2 | Comments
The first step of a nutritional assessment usually involves adminis-
tering a screening tool, so that patients can be stratified by their 
risk of malnutrition. Tools such as the Royal Free Hospital—Global 
Assessment (RFH- GA),73	 or	 the	 Royal	 Free	 Hospital—Nutritional	
Prioritizing Tool74,75 have been developed and applied, but not 
extensively validated, in patients with cirrhosis. There are several 
reasons why it seems reasonable to consider all patients awaiting 
LT potentially at risk of malnutrition, however. For instance: (a) the 
prevalence of nutritional changes, alone or in combination, and their 
impact on outcome are very high; (b) nutritional disorders are poten-
tially modifiable factors; and (c) patients with cirrhosis often have 
concomitant clinical complications that require different, and some-
times conflicting, nutritional approaches.
The criteria for diagnosing nutritional disorders developed 
by international scientific societies depend on how they are ad-
opted.57,75	 Unfortunately,	 the	 accuracy	 of	 methods	 developed	
for the general population is often limited by the changes in body 
composition that coincide with advanced cirrhosis. In the last de-
cade sarcopenia has emerged as the “core issue” in the nutritional 
assessment of such patients because it can be objectively mea-
sured and quantified.75,76
Measuring	 muscle	 mass	 on	 CT	 scans	 or	 MRI	 is	 currently	 the	
gold standard for assessing a patient for sarcopenia. Among the 
several techniques proposed,75	calculating	the	cross-	sectional	PMA	
normalized by height squared or body surface area,77 or the third 
lumbar vertebra skeletal muscle index normalized by height squared 
(L3SMI)78 have been validated for use in patients with cirrhosis 
awaiting	LT	(PMA	cut-	off:	1561	mm2	in	men,	1464	mm2 in women;77 
L3SMI	cut-	off:	<50	cm2/m2 in men and <39 cm2/m2 in women78).
Since	abdominal	CT	scan	or	MRI	are	part	of	the	assessment	of	
potential candidates for LT, these measurements can be obtained 
without having to perform additional tests (though they may de-
mand the use of specific software).
Sarcopenia is also characterized by impaired muscle function, 
and thus contributes heavily to physical frailty, which has recently 
been identified as an independent risk factor of poor outcomes 
before and after LT.79	Muscle	 function	 is	 easy	 to	 assess	with	 the	
hand- grip strength test and a few physical exercises (4- m walking 
test,	chair	standing	test,	6-	minute	walking	test).	The	results	of	these	
tests correlate positively with the degree of sarcopenia. The tests 
are easy to perform and reproducible, and consequently suitable for 
use in longitudinal assessments to monitor the efficacy of nutritional 
interventions.80
4.3 | Question 3
How can we manage the nutritional care of patients with cirrhosis 
awaiting LT?
4.3.1 | Statements
Patients awaiting LT should follow a nutritional care pathway, system-
atically involving a global nutritional assessment, the planning of a 
nutritional care program and the monitoring of nutritional outcomes. 
(B, I)
Nutritional	care	should	be	customized	to	meet	the	needs	of	indi-
vidual patients, and preferably managed by a dedicated dietitian/nu-
tritionist, in close collaboration with the patient’s hepatologist. (B, I)
Regular counselling is recommended to ensure patients’ adher-
ence to their nutritional recommendations. (B, I)
The general recommendations regarding energy and dietary intake, 
based on the international guidelines, can be summarized as follows: 
(A, I)
1. Provide	 30-35	kcal/kg	 of	 dry	 body	 weight	 a	 day	 (50%-60%	 of	
calories as carbohydrates; 20%-30% as fat).
2. Avoid unnecessary dietary restrictions.
3. Provide 1-1.5 g of protein per kg of body weight a day (in patients 
with hepatic encephalopathy, consider reaching the protein intake 
needed by including vegetable proteins, dairy proteins, and/or 
oral branched chain amino acid supplementation).
4. Distribute	the	dietary	intake	over	4-6	meals	a	day,	including	a	late	
evening snack.
5. Consider the need for vitamins and trace elements, depending on 
patients’ symptoms and/or serum levels.
6. Patients who are severely malnourished and/or unable to achieve 
a sufficient intake from their diet or oral supplementation may 
require enteral (preferably) or parenteral nutrition.
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Sarcopenia should be treated using a combined approach based on 
an adequate intake of proteins, including supplementation with oral 
branched chain amino acids, and vitamins, especially vitamin D (see 
general recommendations above), and regular suitably adapted physi-
cal exercise. (B, I)
Obesity should be controlled by means of a comprehensive life-
style management, including three key components: a lower calorie 
intake, more physical activity and behavioural intervention. (A, I)
In patients with morbid obesity not adhering and/or responding 
to a lifestyle management approach, bariatric surgery can be consid-
ered prior to LT, but this option suffers from a higher mortality rate in 
patients with decompensated cirrhosis (Child B/C) and portal hyper-
tension. (B, IIa) Combined LT and sleeve gastrectomy may be an option 
for managing patients with morbid obesity. (B, IIb)
4.3.2 | Comments
Patients awaiting LT form a very heterogeneous population in terms 
of their clinical conditions and nutritional status. As an example, the 
spectrum can go from a normal- weight Child A patient with HCC to 
a sarcopenic Child C patient with ascites and/or hepatic encepha-
lopathy with diabetes. The management of nutritional disorders at 
individual patient level should therefore always take into account 
the concomitant clinical manifestations of the disease, which often 
require apparently conflicting dietary approaches. For instance, how 
do we establish an adequate protein intake for a sarcopenic patient 
with hepatic encephalopathy and/or renal failure?
As well as a very often low calorie intake because of anorexia, 
nausea and vomiting, early satiety, and an inadequate digestion and 
absorption of nutrients, patients with cirrhosis tend to have a very 
poor adherence to general nutritional recommendations. There are 
several reasons for this behaviour, including patients’ and physi-
cians’ poor knowledge of the content of food and drink, low socio- 
economic conditions, lack of family support, physicians spending too 
little time on explaining dietary recommendations in routine clinical 
practice and poor compliance with prescribed diets.81
Hence, the need for nutritional interventions to be based on 
the specific needs of individual transplant candidates, and provided 
wherever possible by certified nutritionists or dieticians, as part of 
a multidisciplinary approach that takes all the above factors into ac-
count, and assures regular counselling and monitoring of adherence 
and results.
Our statements regarding the general nutritional indications for 
patients with cirrhosis, and for the treatment of sarcopenia and obe-
sity, reflect the recommendations of the major international scien-
tific associations and experts in the field.82-84
Finally, bariatric surgery has been proposed as a novel approach 
to treating severely obese patients listed for LT and failing to re-
spond to a controlled diet and physical exercise. Patient selection 
issues and the timing of such surgery are still debated. For now, the 
option of bariatric surgery prior to LT appears to be limited to Child 
A patients because of the high mortality and morbidity rates in Child 
B and C patients.85 A promising alternative is to combine a sleeve 
gastrectomy with the transplant surgery, but only a few such cases 
have been described so far.86
4.4 | Question 4
Can physical activity improve the nutritional status of patients 
awaiting LT?
4.4.1 | Statements
Regular physical activity has a positive effect on aerobic capacity, 
muscle loss and strength, and QoL in patients with cirrhosis awaiting 
LT. It also helps obese patients to lose weight. (A)
The general recommendations on physical activity available for 
adults	 aged	 50-	64	with	 clinically	 significant	 chronic	 conditions	 or	
functional limitations affecting their mobility, fitness or physical ac-
tivity can be applied to cirrhotic patients. (C, IIa) A personalized pro-
gram of physical activity may be useful in patients awaiting LT. (B, IIa)
Particular caution is needed for patients with decompensated cir-
rhosis: physical activity should always be associated with adequate 
dietary intake; and assessing their aerobic capacity can orient the 
customization of their activity programs. (B, IIa)
4.4.2 | Comments
Patients with cirrhosis awaiting LT are scarcely active physically, 
severely out of condition, with an impaired aerobic capacity, and 
these factors increase their risk of frailty.87 A reduced maximal ex-
ercise capacity is associated with a high risk of 90- day and 1- year 
post- transplant mortality, perioperative complications and early in- 
hospital mortality.88-90
Regular physical activity is thought to be important to avoid 
frailty, improve QoL, and maintain an adequate physical condition.87 
Randomized clinical trials, on albeit small samples of patients with 
cirrhosis awaiting LT, have demonstrated that adapted physical ac-
tivity programs are effective in increasing maximal oxygen uptake, 
6-	minute	walking	distance,	and	muscle	strength,	with	no	significant	
side effects.91-93 A recent study showed that an intensive lifestyle in-
tervention is also effective in obese/overweight patients with com-
pensated cirrhosis, since diet and moderate physical exercise favour 
weight loss and, most notably, reduce portal pressure.94
The international recommendations for physical activity in adults 
aged	 50-	64	 with	 clinically	 significant	 chronic	 conditions	 or	 func-
tional limitations affecting their mobility, fitness or physical activity 
levels95 can generally be adopted, given that no guidelines have been 
developed specifically for patients with cirrhosis. It is nonetheless 
important to emphasize that physical activity in patients with de-
compensated cirrhosis should be customized, and always coupled 
with appropriate nutritional supplementation because exercising 
under an insufficient nutritional intake can paradoxically accelerate 
protein catabolism and consequent muscle loss in patients with ad-
vanced cirrhosis.87 A multidisciplinary approach thus seems particu-
larly useful for patients with more advanced disease.
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4.5 | Question 5
Is nutritional status and its management clinically relevant to the 
long- term outcome of patients after LT?
4.5.1 | Statements
Weight gain, obesity and metabolic syndrome are very common after 
LT, posing a major risk in terms of a higher incidence of cardiovas-
cular disease in long- term survivors. Sarcopenia can persist, or even 
become worse, in the early months after LT. Physical activity is usu-
ally insufficient. (A)
Metabolic syndrome and/or obesity should be managed taking a 
comprehensive lifestyle approach, including three key components: 
a lower calorie intake, more physical activity and behavioural inter-
vention. (A, I) Sarcopenia could be managed according the indica-
tions provided for patients on the waiting list for LT. (C, I)
Patients should be assessed soon after LT by a MDT in order to 
plan a personalized, long- term program of nutritional counselling 
and exercise training. (B, I)
4.5.2 | Comments
Cardiovascular diseases are a major cause of long- term morbidity 
and mortality after LT. This is hardly surprising, given the very high 
prevalence of risk factors among transplant recipients, who have 
obesity in 25%- 30% of cases; type 2 diabetes in 30%- 40%; and hy-
perlipidaemia	 in	 45%-	70%.96,97 Overall, the diagnosis of metabolic 
syndrome	can	be	established	in	40%-	60%	of	LT	recipients,	judging	
from different studies.96,97 The onset of metabolic syndrome also 
seems to correlate inversely with the amount of physical activity.98
The maximal rate of increase in fat mass usually coincides with 
the	 first	year	after	LT.	Meanwhile,	 sarcopenia	may	persist	or	even	
become worse. This combination can lead to a condition of sarcope-
nic obesity, which may easily go misdiagnosed because of the con-
comitant	increase	in	BMI.99
Studies on whether diet and physical exercise can improve long- 
term post- LT outcomes are few,100,101 but multidisciplinary lifestyle 
intervention programs can plausibly produce positive results in this 
population at high risk of cardiovascular events.87
5  | LIVING DONOR LIVER 
TR ANSPL ANTATION: UPDATE AND 
PERSPEC TIVES
All transplants from living donors to be performed in Italy must 
comply with the requirements of primary Italian legislation (Legge 
16/12/1999,	n.	483	“Norme per consentire il trapianto parziale di fe-
gato”	 [G.U.	 n.	 297	 del	 20/12/1999]	 e	 Decreto	Ministeriale	 della	
Salute	 del	 16/04/2010,	 n.	 116	 “Regolamento per lo svolgimento 
delle attività di trapianto di organi da donatore vivente”	[G.U.	n.	172	
del	26/07/2010]).	All	health	professionals	involved	in	living	donor	
liver transplantation (LDLT) should acknowledge the broad array 
of complex moral issues in this field and ensure that good eth-
ics consistently underpin their clinical practice.102,103 Regardless 
of the benefit to the potential recipient, the safety and welfare of 
the potential living donor should always take precedence over the 
needs of the recipient.
The key preoperative, operative and post- operative aspects 
surrounding liver donations from a living donor have been devel-
oped and published in two recent reports by the International Liver 
Transplant Society, and the British Transplantation Society, and 
they	have	been	adopted	as	practical	guidelines	in	the	USA	and	UK	
respectively.104,105
5.1 | The donor
5.1.1 | Question
Which general donor selection criteria are accepted to obtain an 
adequate partial allograft while also ensuring an acceptable donor 
safety?
Statements
In	Italy	donors	must	be	from	18	to	60	years	old.
The medical work- up for older donors should be particularly 
strict (not graded). All potential donors should be screened for car-
diovascular disease, and there should be a low threshold for their 
exclusion if significant risk factors are found. (B, I)
The goals of donor assessment are to ensure that: (a) an adequate 
partial allograft can be safely procured; (b) there is no risk of disease 
transmission from donor to recipient; and (c) the donor understands 
the process and would be able to overcome any psychological con-
sequences. (C, I)
It is generally recommended that the recipient’s graft to body 
weight ratio (GRBWR) be no lower than 0.8%, though a lower 
GRBWR can be considered in selected cases. (C, IIa)
The donor’s remnant liver volume should be no less than 30%–
35% of the initial volume of the whole liver. (C, I)
If fatty liver is suspected, a biopsy is needed: macrovesicular 
steatosis greater than 30% is an absolute contraindication for liver 
donation. (C, I)
Any disease transmissible from donor to recipient contraindi-
cates LDLT. (C, I)
A multidisciplinary approach is needed for the donor’s psycho-
logical assessment. (C, IIa)
Hospitals and teams involved in LDLT should devise a framework 
on how to respond to a potential living donor severe issue.
In the event of the donor’s death, a root cause analysis should 
be conducted and the centre’s LDLT program should be suspended 
pending the outcome of the investigation. (B, IIa)
A documented national disaster and media communication plan 
agreed by all centres performing LDLT should be adopted. (B, IIa)
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Comments
Donor safety is the core issue, and the goals of donor assessment 
are to ensure that: (a) an adequate partial allograft can be safely 
procured; (b) there is no risk of disease transmission from donor to 
recipient; and (c) the donor understands the process and would be 
able to overcome possible psychological consequences. The do-
nor’s remnant liver volume should be no less than 30%- 35% of the 
initial volume of the whole liver to avoid post- operative hepatic 
insufficiency, remnant loss, and death.106-108 For the recipient, 
it is generally recommended that the GRBWR be no lower than 
0.8% to avoid small for size syndrome and early post- operative 
graft failure.105,109 A lower GRBWR can be considered for se-
lected recipients with a good functional status and minimal portal 
hypertension.109,110
Donors should be checked for any chronic liver disease. 
Macrovesicular	steatosis	greater	than	10%	is	a	concern;	and	beyond	
30% it becomes an absolute contraindication for donation and raises 
the risk of graft failure in the recipient.111-114 Potential donors with 
predisposing factors for fatty liver (obesity, diabetes, dyslipidaemia) 
and/or imaging findings consistent with fatty liver should undergo 
biopsy during the pretransplant assessment to clearly ascertain the 
extent of macrovesicular steatosis.114
Living liver donation carries a significant donor mortality es-
timated at between 0.1% and 0.5% for left and right liver do-
nors respectively.115-118 A morbidity rate of 20%- 35% is also 
expected.115,116,119,120 Complications such as pulmonary embolism, 
myocardial infarction, peptic ulcer and liver failure121,122 have re-
sulted in donor deaths. It is therefore crucial to provide for inten-
sive monitoring and the early identification of any post- operative 
complications.
5.1.2 | Question
Which specific process should be used to inform donors appropri-
ately, arrange for donor advocates and obtain donors’ consent?
Statements
The living donor should be offered the best possible environment 
in which to make a voluntary and informed choice about donation 
(not graded).
Separate clinical teams for donors and recipients are usually 
considered best practice, and a donor advocacy team should be as-
signed to every potential living liver donor.
Informed consent should include full information about the po-
tential surgical, medical, financial and psychological risks (including 
death) of a hepatectomy. (C, I)
All potential donors should be assessed by a mental health 
professional, preferably a member of the donor advocacy team. 
(B, I)
Donor safety and the availability of sufficient time for informed 
consent should drive the pace of the donor work- up, even when the 
recipient is very ill. (A, I)
Comments
From a psychological viewpoint, living donation can be challenging. 
Donors are aware that the chances of extending the recipient’s life 
depend on their decision to donate, but they should also be aware 
that post- transplant outcomes cannot be assured. Donors also need 
to understand that donation itself carries a potential risk of mortality 
and complications. That is why assessing the donor’s psychological 
status and stability is essential.
The process of obtaining appropriate donor consent is summa-
rized well by Gordon,117 and includes: (a) assessment of donor’s com-
petence to make decisions; (b) disclosure of information; (c) donor’s 
comprehension of the information; (d) a voluntary decision by the 
donor to donate, free from coercion; and (e) donor’s agreement to 
undergo the procedure.
5.1.3 | Question
What is involved in the recommended presurgical donor work- up?
Statements
A	CT	scan	or	MRI	of	the	donor’s	liver	should	be	performed	with	an	
intravascular contrast. (A, I)
Three- dimensional reconstructions, using either in- house or pro-
prietary software, are recommended to obtain detailed 3D models 
of the donor’s liver for volumetric analysis and to ascertain its vascu-
lar/biliary anatomy. (B, I)
Conventional arteriography and hepatic venography should only 
be used in exceptional circumstances, when conventional contrast- 
enhanced CT fails to provide adequate imaging information. (B, I)
Magnetic	resonance	cholangiopancreatography	is	the	gold	stan-
dard for biliary anatomy. Endoscopic retrograde cholangiopancrea-
tography as well as intraoperative cholangiography should not be 
anymore used to assess biliary anatomy. (B, I)
Steatosis assessment:
1. Ultrasound	 can	 be	 used	 as	 a	 screening	 tool.	 MRI	 provides	 a	
better picture than CT for grading steatosis, and is the pre-
ferred option. (A, I)
2. With CT, the liver-to-spleen attenuation ratio (difference be-
tween hepatic and splenic attenuation) and blood-free hepatic 
parenchymal attenuation should be used. The maximum amount 
of steatosis is not well-defined, but acceptable limits range from 
10% to 30%. (B, I)
To calculate the liver volume, the percentage of steatosis should be 
subtracted from the estimated liver mass available for the graft. (C, IIa)
Liver biopsy is reserved for the potential donor with unexplained 
abnormalities	on	liver	function	tests,	a	BMI	approaching	30	kg/m2, 
or aspartate aminotransferase > alanine transaminase. (B, IIa)
Donors initially rejected because of steatosis can be consid-
ered for a low- calorie “defatting diet” and reassessment with new 
volumetric tests. Fibroscan can be a useful method to monitor 
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such defatting process, potentially reducing the need for a re- 
biopsy. (B, I)
To calculate the donor graft volume, software- assisted image 
post- processing is recommended because it is the most accurate as-
sessment method. (A, I)
Published formulas with error rates of less than 10% should be 
used to calculate the recipient’s standard liver volume. (B, I)
Comments
Any past or present condition carrying a significant risk of periop-
erative complications in the donor makes living donation contraindi-
cated unless it can be corrected. The donor’s pretransplant work- up 
should therefore include an exhaustive cardiovascular assessment. 
Echocardiography should be routine. Additional investigations, such 
as stress echocardiography and/or coronary angiography, may be 
needed. Transmissible disease is another contraindication for living 
donation. Appropriate blood tests should be used to screen system-
atically for asymptomatic inherited coagulation disorders involving 
liver synthesis (e.g, Leiden factor V, protein C/protein S deficiency, 
anti- thrombin deficiency).118
5.1.4 | Question
What is involved in the recommended donor aftercare program and 
clinical follow- up?
Statements
Laboratory tests for liver function and platelet counts should be 
conducted during the follow- up for at least 1 year. (C, IIa)
All donors should be advised to have annual checkups with pri-
mary care providers for the rest of their lives. (C, I)
Comments
Most	living	donors	will	return	to	a	previous	level	of	physical	perfor-
mance and psychological status over the course of 1 year.123,124 With 
only 25 years of experience of LDLT, the long- term consequences of 
living donation have yet to be fully understood.
5.2 | The recipient
5.2.1 | Question
What should be the specific approach to the management of recipi-
ents of a living donation?
Statements
Living donor liver transplantation should only be performed at spe-
cialist centres by a multidisciplinary transplant team. (A, I)
Decision- making should be multidisciplinary and meet the stan-
dards for transplant services in European countries. (A, I)
The Italian standard for transplant benefit, an overall graft and 
patient survival of more than 50% at 5 years, is the recommended 
standard for both deceased donor LT (DDLT) and LDLT. (B, I)
Following similar current policies of western countries, potential 
recipients with HCC need to fall inside the currently accepted guide-
lines for DDLT. (B, I)
Following similar current policies of western countries, as in the 
case of DDLT, only recipients with a more than 50% chance of sur-
vival at 5 years should be considered for LDLT. (A, IIa)
Adult- to- adult LDLT is associated with a significant learning 
curve within the first 20 cases. All emerging centres should have 
access to mentoring over this period. (B, I)
There is a 40% risk of complications in the first year after right 
liver lobectomy. (B, I)
The	incidence	of	donor	death	is	not	well	defined,	but	in	the	USA	
and Europe it is approximately 0.2%. (B, IIa)
Reporting of donor death and morbidity is mandatory via the 
National	Transplant	Centre	(CNT)	incident	reporting	process.	(A, IIa)
Recipient outcome and graft survival 12 months after LDLT 
should be at least as good as after DDLT. Graft survival crucially de-
pends on case mix, but averages around 80% at 1 year after LT. (B, I)
It is accepted that the frequency of biliary complications in LDLT 
recipients is 25%- 35%, which is higher than after DDLT. (B, I)
Comments
In	a	10-	year	follow-	up	study	that	objectively	graded	36	categories	
of	complications	(including	time	to	their	resolution)	in	471	cases	
of	DDLT	and	565	of	LDLT,	 the	 risk	of	graft	 loss	and	death	 (haz-
ard ratio 0.89, P	=	.60),	 the	 time	 to	 resolution	of	 complications,	
and	 the	 overall	 incidence	 of	 complications	 (70%)	 did	 not	 differ	
between LDLT and DDLT.125 The rates of biliary- related complica-
tions	and	hepatic	artery	thrombosis	were	higher	 in	LDLT	(6%	vs	
4% in DDLT). On the other hand, DDLT was more likely to asso-
ciated with ascites, intraperitoneal hemorrhage, cardiac morbid-
ity, and pulmonary oedema, and with a 2.5- fold higher chance of 
CKD in stages 4 and 5 according to the Kidney Disease, Improving 
Global Outcomes (KDIGO) scale.125 Whereas the survival benefit 
of LDLT relative to DDLT at 10 years has been confirmed,126,127 
the detrimental effect of severe renal dysfunction on mortality 
after LT will continue to negatively affect survival after DDLT.128 
The future is bright for LDLT recipients: with experience gained 
worldwide, not only has the related morbidity dropped to below 
the	 thresholds	 for	LT	established	 in	national	studies	 like	 the	US	
A2ALL cohort, but underserved recipients who would never be 
eligible for DDLT have been added to the pool of successful LT re-
cipients.129-133 There is now strong evidence, magnified at experi-
enced centres, of LDLT providing a sustained benefit to recipients 
with	low	MELD	scores	(<15),	and	a	lower	mortality	on	the	waiting	
list is only part of the reason.126,134 Candidates who have decom-
pensated cirrhosis but are otherwise transplantable, and those 
whose	low	MELD	scores	underestimate	their	risk	of	death,	as	in	
patients with hyponatremia,135,136 refractory ascites,137 or recur-
rent variceal bleeding and contraindications to transjugular intra-
hepatic portosystemic shunt138 are just a few of the subgroups 
of recipients benefiting from LDLT.127 A prospective, long- term 
study on HCC treatment with the intention to transplant with 
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either type of graft further clarified the art and science of tumour 
biology and liver- directed ablative HCC treatment in preventing 
post- LT HCC recurrence from interfering with the choice of LDLT 
or DDLT for optimal care.139 A Japanese study found that, within 
programmed	criteria,	and	inside	or	outside	the	Milan	criteria,	the	
Kyushu criteria included the largest number of patients with HCC 
(95.6%	of	 those	meeting	 the	Milan	 criteria,	 and	41.2%	of	 those	
outside them).140,141 The Kyoto criteria included the next highest 
number	of	patients	with	HCC	(65.7%	inside	and	17.6%	outside	the	
Milan	criteria),	but	with	a	5-	year	survival	of	91.7%,	and	a	low	HCC	
recurrence	 rate	 (4.6%	 at	 5	years	 for	 patients	 outside	 the	Milan	
criteria).140 In patients with HCC undergoing ablation or resection 
followed by LT, the largest and longest prospective study (includ-
ing DDLT and LDLT) found the lowest rate of HCC recurrence 
in	patients	with	≥3	months	elapsing	from	HCC	ablation	to	LT.139 
Validating this finding, an interval <3 months since the last treat-
ment (P	=	.01),	and	serum	PIVKA-	II	levels	≥300	mAU/mL	(P = .03) 
were independent predictors of a shorter recurrence- free sur-
vival in a multivariate analysis conducted as part of a retrospec-
tive study on 114 patients undergoing LDLT for recurrent HCC.142
6  | HEPATOCELLUL AR C ARCINOMA AND 
LT:  IS IT TIME TO E XPAND THE CRITERIA IN 
ITALY?
In	Italy,	44.4%	of	patients	who	underwent	LT	between	June	2007	
and	May	2009	had	HCC	as	their	primary	indication	for	transplan-
tation.	Much	 the	same	picture	emerges	 from	more	 recent	 series	
from	the	Unites	States,	where	HCC	was	the	most	common	indica-
tion for both joining the waiting list and LT.23,143 The advent of 
antiviral treatment for hepatitis C virus (HCV) infection capable of 
halting or slowing the progression of chronic liver disease (but not 
of abolishing the risk of HCC) has revolutionized the population 
that might need LT. This is particularly true in Italy, where chronic 
HCV infection, with or without HCC, was the main etiological fac-
tor	 in	 patients	 transplanted	between	2007	and	2009.23,144 With 
a projected further increase in the cases of HCC, the pressure to 
expand the criteria for LT in patients with HCC is consequently 
significant. The fact that the pool of liver donors has not expanded 
poses important questions, however, regarding: the appropriate 
(upper) limit for considering LT for HCC; and, if the currently rec-
ommended limits are expanded, the best way to establish new 
boundaries that can avoid any misuse of a limited resource. Other 
as yet unanswered questions concern how to assess response to 
tumour downstaging treatments and, more importantly, how to 
judge the efficacy of any expanded criteria.
6.1 | Question 1
What are the minimal outcome requirements for potentially ex-
panded criteria for LT in patients with HCC?
6.1.1 | Statement
Any expansion of the criteria for LT in patients with HCC beyond the 
Milan	criteria	should	ensure	a	5-	year	survival	 rate	of	at	 least	61%,	
which is the figure needed for the benefit of LT in such patients to 
outweigh the possible harm caused to other patients on the waiting 
list. (A, I)
6.1.2 | Comment
As well as complying with the currently accepted overall and 
recurrence-	free	 survival	 rates	 (i.e,	 the	 Milan	 criteria),	 expanded	
criteria for LT in patients with HCC should allow for the popula-
tion that can be listed for LT to grow only to a level that is rea-
sonably acceptable in terms of organ availability and transplant 
waiting time.145	 More	 importantly,	 this	 expansion	 should	 not	 be	
detrimental to the chances of a transplant for patients on the wait-
ing list who have ESLD without HCC. According to studies based 
on	Markov	models	and	using	data	from	the	USA,	patients	outside	
the	Milan	criteria	would	need	to	achieve	a	5-	year	survival	rate	of	
at	 least	61%	 to	prevent	 a	 substantial	 drop	 in	 the	 life-	years	 avail-
able to the whole population of candidates for LT.146 The effect on 
non- HCC patients could vary widely, depending on the composi-
tion of the population on the waiting list, and on the availability 
of donor livers at a given centre and in a given transplant region. 
Theoretically, any decision made by transplant centres to expand 
their criteria for HCC should take into account the current mortal-
ity on their waiting list, and only be adopted if it is low and will not 
be substantially increased by adding the expanded- criteria cases. 
In	Italy,	the	widespread	application	of	the	“HCC-	MELD”	score	has	
been proposed by the Italian Board of Expert in the Field of LT 
as a means to allow equity of allocation between HCC and ESLD 
patients on a common liver transplant waiting list, and therefore to 
obviate this potential inequality even considering expanded criteria 
for transplantation for HCC patients.147
6.2 | Question 2
Which parameters should be used to define expanded criteria: mor-
phology, biomarkers, histology?
6.2.1 | Statements
Combining morphometric measurements and biochemical mark-
ers seems to produce better results than including either of 
these parameters alone in expanded criteria for LT in HCC pa-
tients. (B, IIa)
Among the models that combine morphometric parameters and 
biomarkers, the alpha- foetoprotein (AFP) model is reproducible and 
accurate, and retains its prognostic capability even when patients’ 
scores change, so it can be proposed as a model for expanding the 
current criteria for listing HCC patients. (B, IIa)
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6.2.2 | Comment
In most of the proposed criteria for expanding the current lim-
its for LT in HCC patients, morphometric considerations (size or 
number of nodules, or both), biomarkers (AFP), and HCC differen-
tiation on preoperative tumour biopsy (tumour grade), alone or in 
various combinations, are used to judge whether the 5- year sur-
vival	rate	would	remain	much	the	same	if	the	Milan	criteria	were	
exceeded.148
The	 French	 National	 Agency	 for	 Organ	 Sharing	 and	
Transplantation	(ABM)	recently	adopted	the	AFP	model	to	select	
HCC patients for LT.149 This model was identified using multivar-
iate analysis on a training cohort, and validated in a more recent 
cohort. It includes AFP with various cut- offs (10- 100- 1000 ng/
mL) to provide a greater degree of granularity, as well as tumour 
number and size.149,150 A scoring system that includes these three 
parameters, using a simplification to obtain a two- tiered classifi-
cation (low vs high risk of recurrence) was able to differentiate 
between	5-	year	recurrence	rates	(8.8%	vs	50.6%,	P < .001), and 
survival	rates	(67.8%	vs	47.5%,	P = .002). The impact of the three 
parameters on recurrence and survival was evident and statis-
tically	significant,	 in	patients	both	within	and	outside	the	Milan	
criteria. It is noteworthy that an estimation of the net reclassifi-
cation improvement indicated that the AFP model significantly 
improved the prediction of recurrence. Among those exceeding 
the	Milan	 criteria,	 38.4%	of	 patients	 in	 the	 training	 cohort	 and	
74.0%	 in	 the	 validation	 cohort	 whose	HCC	 did	 not	 recur	 were	
classified as low- risk using the AFP model. Similarly, of the pa-
tients	meeting	 the	Milan	criteria	whose	cancer	 recurred,	21.6%	
and 21.4% in the training and validation cohorts, respectively, 
would have been classified as high- risk using the AFP model. 
The predictive capacity of the AFP model was consistent when 
it was applied to patients re- assessed after down- staging, and 
in the transition from a high- to a low- risk score. The model’s 
predictive power was recently validated independently in a 
multicentre Italian study, in which the AFP model confirmed its 
ability to differentiate between patients at low- and high- risk of 
recurrence, and their 5- year survival in a population with mainly 
post- viral cirrhosis.150 A competing risk analysis taking the com-
peting risk of death unrelated to HCC showed that the AFP 
model	performed	better	 than	 the	Milan	criteria.	The	study	also	
showed a closer association of the AFP model with predictors 
of recurrence on pathology of the explanted liver, such as the 
presence of microvascular invasion and poor differentiation.150 
A further external validation of this model came from a study in 
Latin America, where the predictive capability of the AFP model 
was replicated, though in this population (as in the Italian pop-
ulation) the model was less accurate for patients with HCC and 
chronic HBV infection.151 At a recent consensus meeting of the 
Liver	Advisory	Group	of	 the	UK	National	Health	Service,	Blood	
and Transplant section, the AFP model was included in the pre- 
existing	UK	criteria.152
6.3 | Question 3
Are there upper limits for rejecting a patient with HCC for LT, and 
starting HCC downstaging?
6.3.1 | Statements
Macrovascular	invasion	and	extrahepatic	spread	are	conditions	that	
preclude patients with HCC from downstaging with a view to LT be-
cause they are associated with unsatisfactory post- LT survival and 
recurrence rates. (A, IIb)
Apart from any absolute contraindications to LT, there is no defi-
nite “upper limit” to HCC downstaging. (B, IIb)
Transplant centres should periodically review the outcome of 
downstaged patients to ensure adequate post- transplant survival 
rates. (C, I)
6.3.2 | Comment
It seems crucial to set a threshold beyond which a patient cannot 
be considered a candidate for LT because their HCC has reached 
a stage that would make the transplant futile, while harming other 
patients on the waiting list. On the other hand, there is debate about 
whether tumour burden (size and number of nodules) actually in-
fluences liver transplantability. It may be that any patient without 
absolute contraindications (such as macrovascular invasion or extra-
hepatic spread) is potentially transplantable irrespective of tumour 
burden, pending successful downstaging to locally or regionally 
preset transplant criteria. This latter approach has recently been 
endorsed by the Italian community of liver transplant surgeons and 
transplant hepatologists. Going a step further, instituting downstag-
ing treatments, then assessing response to such treatment in terms 
of	reconciling	HCC	stage	with	accepted	boundaries	(e.g,	Milan	crite-
ria; AFP model), using other available means that may help us to as-
sess tumour response to treatment or progression during the wait, 
and monitoring the dynamics of these parameters while awaiting 
LT as a “test of time” may help us to identify rapidly progressing tu-
mours, and thus enable us to make appropriate decisions.147
6.4 | Question 4
Are there any predictors of successful downstaging? If so, can they 
be used to modify the indication for LT?
6.4.1 | Statements
Tumour burden (number and diameter of nodules, total tumour vol-
ume, and HCC growth pattern) is associated with:
1. The success of downstaging treatments, in terms of the re-
duction in this burden; (C, IIb)
2. Post-LT recurrence; (B, IIa)
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3. Overall survival after LT. (C, IIb)
Serum AFP levels before or on completing downstaging treat-
ments, or at the time of LT, are associated with:
1. Downstaging efficacy; (C, IIb)
2. Waiting list drop-out; (B, IIa)
3. HCC recurrence after LT; (B, IIa)
4. Time to recurrence; (C, IIb)
5. Disease-free survival; (B, IIa)
6. Overall survival. (C, IIb)
Response to treatment, and its stability over time predict post- 
transplant HCC recurrence, and are associated with time to recur-
rence. (C, IIb) Complete response to downstaging is associated with 
overall survival. (B, IIa)
The use of heterogeneous inclusion criteria, a shortage of 
randomized studies, the adoption of different characteristics/
thresholds for the same parameter, and the lack of standardized 
measures of downstaging treatment efficacy make it impossible 
to identify parameters capable of unequivocally predicting the 
success of downstaging, or provide consistent and clear- cut indi-
cations for LT on the basis of response to downstaging treatment. 
(C, I)
It is strongly recommended that centres establish well- defined 
written parameters (to be verified and updated in the light of out-
comes) in terms of initial criteria, response to treatment, and mainte-
nance of response over time for transplantability. (C, I)
6.4.2 | Comment
Patients with HCC listed for LT while exceeding the currently ac-
cepted criteria for transplantation usually undergo procedures 
aiming to reduce their tumour burden, and thus avoid waiting list 
drop- out because of tumour progression beyond transplantabil-
ity. When using expanded criteria, one of the most relevant issues 
concerns the need to identify parameters capable of predicting 
which patients will fail to respond to measures to reduce their tu-
mour burden, and therefore benefit from other downstaging treat-
ments. Several studies tried to establish which parameters best 
predicted successful downstaging, but their value is limited by dif-
ferences, for instance in: the numbers of patients involved (ranging 
from	22	 to	 271);	 the	 populations	 considered	 (with	 some	 reports	
including patients with macrovascular invasion); the criteria for de-
fining successful downstaging; the cut- offs used for the same pa-
rameter (e.g, AFP levels); the types of downstaging treatment; the 
radiological criteria used to assess response to treatment; and the 
duration of the follow- up to establish a consolidated response to 
downstaging.153-158 Lastly, and most importantly, no randomized 
controlled trials have examined this issue, and very few of the pub-
lished studies were prospective. All these shortcomings clearly 
limit the chances of drawing any firm conclusions regarding this 
important issue.
6.5 | Question 5
How should we assess the efficacy of expanded criteria, in terms of 
intention- to- treat or post- transplant survival?
6.5.1 | Statements
In transplantable patients who undergo downstaging, survival 
should be assessed by means of an intention- to- treat analysis. (C, IIb)
In transplanted patients, survival should be expressed at 5 years 
using a per- protocol analysis. (A, I)
6.5.2 | Comment
When assessing the efficacy, in terms of survival, of adopting ex-
panded criteria for transplanting HCC patients, we should consider 
“oncological survival” (for all patients with HCC who receive a trans-
plant), and “transplant survival” (considering transplanted patients 
with and without HCC). Judging the efficacy of the expanded cri-
teria should thus avoid the “double mortality” of patients with HCC 
whose tumour recurs and who die after LT, and of potential LT recipi-
ents without HCC who do not receive a transplant.148,159,160 Excess 
waiting list mortality because of the listing of patients who cannot 
wait and who have to drop out as a result of uncontrollable HCC 
progression should be taken into account as well. In this regard, the 
thresholds for initiating downstaging, and for considering it success-
ful should be clearly defined at each transplant centre, and prefer-
ably the same across centres. The intention- to- treat criterion seems 
to be more pertinent to patients who may be eligible for downstag-
ing because it assesses patients who have reached the downstaging 
threshold and are waiting for a transplant, thus reflecting the per-
formance of the listing criteria adopted (e.g, risk of overtreatment 
and drop- out because of uncontrollable liver failure; risk of drop- out 
because of inadequate expansion of transplant criteria and conse-
quent uncontrollable progression of HCC). On the other hand, per- 
protocol criteria only consider the survival of patients who have had 
a transplant, with the risk of evaluating survival in favour of patients 
with a disease that has a benign biological behaviour, excluding mor-
tality on the waiting list among patients with aggressive disease or 
an excess tumour burden.
7  | HOW TO DE AL WITH DIREC T- AC TING 
ANTIVIR AL TRE ATMENT FAILURE BEFORE 
AND AF TER LT
Infection with HCV is the most common indication for LT world-
wide.161,162 In viraemic patients, HCV infection nearly always recurs 
after transplantation, with a significant impact on patient and graft 
survival. HCV patients on the waiting list generally belong to one 
of two different clinical scenarios of HCV disease, i.e, liver decom-
pensation (Dec- HCV, with or without HCC), or HCC in compensated 
disease (HCC- HCV). Historically, attempts to eradicate HCV before 
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LT had been disappointing, due largely to significant safety concerns 
relating to the use of interferon. The treatment of HCV recurrences 
after LT also suffered from a very low applicability rate, safety con-
cerns and a limited efficacy.163
The approval of safe and effective DAAs has substantially 
changed the landscape of treatment for patients with decompen-
sated cirrhosis, as well as for transplanted patients. The most im-
portant reasons for treating Dec- HCV patients on the waiting list 
for LT are: to improve their liver function, aiming for “delisting”; 
to improve their QoL; and to reduce mortality on the waiting list. 
The data supporting this strategy come from various sources. In 
the European study promoted by ELITA 20% of patients with Dec- 
HCV could be delisted thanks to their clinical improvement.164 A 
recent Italian study on the real- life compassionate use of sofos-
buvir	in	HCV	patients	listed	for	LT	found	that	MELD	scores	could	
be	brought	down	to	satisfy	a	delisting	rule	in	17.4%	of	47	patients	
with severely impaired liver function.165 There is also evidence of 
a longer survival and better QoL while on the waiting list.166,167 
Negativization	 of	 viraemia	 prior	 to	 LT	 has	 also	 been	 associated	
with lower rates of early allograft dysfunction in HCV- positive LT 
recipients.168
In the treatment of patients with HCC and HCV, the main goal 
of DAA has been to prevent HCV reinfection after LT.169 Pre- LT 
DAA	 therapy	 effectively	 prevented	HCV	 recurrence	 in	95%	of	61	
Child- Pugh A patients, providing a minimum 30- day period of viral 
suppression elapsed before LT. A bridging strategy enabled graft 
reinfection to be prevented in most of the patients enrolled in 
the Italian ITACOPS study.165,170	No	solid	data	exist	 at	present	on	
whether preventing decompensation by eradicating the virus would 
enable the use of downstaging therapies for HCC.
7.1 | Question 1
What is the rate of DAA failure and its clinical impact in the pretrans-
plant setting?
7.1.1 | Statement
The overall HCV eradication rate in cirrhotic patients is high, but 
always lower in those with advanced cirrhosis. The rate of failure 
in this patient population is due mainly to viral relapse, and ranges 
between	11%	and	17%	in	trials	and	real-	life	cohort	studies.	(A, I)
Treatment failures should be minimized by identifying predictors 
of a negative response. This could prompt the adoption of a pro-
longed scheme including Ribavirin within current Italian regulatory 
agency rules. (B, IIa)
If there is a strong likelihood of DAA failing in patients with high 
MELD	scores,	the	treatment	could	be	delayed	until	after	LT,	(B, IIa) 
bearing in mind that therapeutic schemes including protease inhibi-
tors are not appropriate as a retreatment strategy in decompensated 
patients. (A, I)
Resistance	testing	 is	mandatory	after	treatment	failure	 in	NS3,	
NS5A,	NS5B,	and	it	can	orient	the	retreatment	strategy.	(A, I)
7.1.2 | Comment
Among various other clinical and transplant- specific considerations 
(expected time on the waiting list, etc.), the decision to treat a pa-
tient with Dec- HCV should take the risk of DAA failure into account. 
This points to the need for a precise definition of the predictors of a 
negative response (very advanced liver disease, presence of ascites, 
hepatic	 encephalopathy,	 albumin	 <2.8	g/dL,	 INR	 >1.7	 and	 biliru-
bin >2 mg/dL) in order to optimize first- line treatment strategies to 
prevent resistance efficiently. The retreatment schemes available in 
this setting are limited, as protease inhibitors are contraindicated in 
decompensated liver disease, and the safety of multiple drug combi-
nations in compensated HCC- HCV is unknown.171 It is important to 
reassess the genotype involved in the event of DAA failure, especially 
in countries where pan- genotyping regimens are unavailable.172
7.2 | Question 2
Is the improvement in liver function following HCV eradication 
enough to balance the risk of DAA failure? In other words, should 
the treatment be given before or after transplantation?
7.2.1 | Statement
The clinical benefit of DAA treatment exceeds the risk of failure. (B, 
IIa)	A	significant	reduction	in	Child-	Pugh	or	MELD	scores	has	been	
reported in 20%- 40% of patients with decompensated cirrhosis 
treated with DAA, and one in four of them could be delisted. There 
have been no warnings about a negative impact of failed viral eradi-
cation treatments on any further decompensation.
As	 baseline	MELD	 scores	 predict	 the	 likelihood	 of	 clinical	 im-
provement and of being delisted, any treatment of patients with a 
high	MELD	cut-	off	should	be	discussed	case	by	case.	(B, IIb)
7.2.2 | Comment
There is an abundance of data on the clinical improvement of Dec- 
HCV patients following HCV eradication. Overall, a sustained viro-
logical response (SVR) is associated with a median 2- point reduction 
in	MELD	score,	a	lower	incidence	of	decompensation	over	12	months	
post- SVR, and a 30% chance of delisting.172-178 In the European 
study coordinated by Belli et al., and involving 11 European centres, 
38/142 treated patients were delisted.165 In the Italian ITACOPS 
study, viral eradication was associated with a better liver function 
in	about	half	of	224	patients	treated.	High	basal	MELD	scores	(≥18),	
severe portal hypertension,179 older age, albumin <3.5 g/dL, and 
hepatic encephalopathy are all associated with a lower chance of 
improvement.
7.3 | Question 3
Based on the magnitude of virological failure in transplanted pa-
tients, what policies are used to minimize DAA failure after LT?
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7.3.1 | Statement
Direct acting antiviral agent (DAA) treatment should be adminis-
tered as soon as possible after LT to avoid graft damage and optimize 
SVR rates. (A, IIa)
If negative predictors are identified, longer treatments and the 
use of ribavirin should be considered, as in the general population, 
and according to Italian regulatory agency rules. (C, IIb)
7.3.2 | Comment
The treatment failure rate with 2nd- generation DAA in HCV pa-
tients after LT ranges between 4% and 12%. In recent “real- world” 
studies, excluding those in which only the suboptimal sofosbuvir and 
ribavirin scheme was used, the rate of virological failure dropped to 
0%-	6%.178,180-183 The factors associated with a poor response are 
the same as in immunocompetent patients (advanced disease stage, 
genotype 3, and a shorter treatment duration). Genotyping should 
be done (unless it has been done only recently, or a reliable report is 
available), and serum storage should be recommended for retrospec-
tive testing.172
No	data	are	available	on	the	best	timing	to	start	treatment	after	
LT, but treatments in pre- and post- LT patients with advanced fibro-
sis and decompensated cirrhosis achieve lower SVR rates, as low as 
60%.171 Several studies have also demonstrated a lower SVR rate in 
patients	with	genotype	1a	and	advanced	fibrosis	(F3-	F4	METAVIR).	
HCV treatment should be started as soon as feasible, not only to 
optimize SVR, but also and especially to reduce the risk of graft 
damage. Treatment with ribavirin, and its duration, after LT is still 
a concern.
Based on the available data, the recommendations are no dif-
ferent from the general guidelines for cirrhotic or non- cirrhotic pa-
tients, except for a close monitoring of immunosuppression levels in 
view of the drug interactions between calcineurin and m- TOR inhib-
itors, and DAA.
8  | CONCLUSION
Although LT is the best treatment for ESLD, there is published 
evidence of very low rates of access to LT for potentially eligible 
candidates with ESLD around the world, largely because they are 
either not referred to liver transplant centres for assessment, or 
their referral comes too late. Even if the organ donor pool is scarce, 
every patient potentially eligible for LT should be referred—at the 
appropriate time—to a transplant hepatologist on principles of jus-
tice and equity, and evaluated and managed with transparency and 
consistency among different centres, to improve their survival—
even for patients who ultimately do not receive a transplant. In 
Italy, a strong effort should be made to: (a) prospectively measure 
referral rates to liver transplant centres, and the latter’s selection of 
patients to place on the waiting list for LT; (b) engage with primary 
care physicians and specialists who manage potential LT candidates 
at meetings and symposia to reinforce the concept of the optimal 
timing for initial referral to a transplant hepatologist, and to spread 
the use of telehealth technologies, such as the “eReferral” website, 
to improve referral to transplant hepatologists and optimize patient 
comanagement.
The growing success of LT over the years has enabled us to 
gradually expand the indications for its use, including patients with 
increasingly severe liver diseases, and refining the selection of ap-
propriate recipient and donor characteristics. Increasingly elderly 
patients, and those with numerous comorbidities are accessing LT 
nowadays. The age of donors is increasing too, along with the need 
to choose the right combination of donor and recipient ever more 
accurately to ensure an acceptable transplant benefit. Although the 
absolute contraindications to LT are few today, there are growing 
numbers of potential candidates with extra- hepatic comorbidities 
that are not always easy to quantify in terms of their impact on sur-
vival and QoL after LT. This type of scenario is destined to become 
more and more common in future, and will probably make it neces-
sary to combine current organ allocation models with the prepara-
tion and validation of more complex prognostic scores than those 
used today in order to calculate the transplant benefit for “difficult 
candidates” for LT.
Sarcopenia, obesity and malnutrition, alone or in combination, 
are common comorbidities in LT candidates and are associated with 
poor outcomes before and after LT, as well as a higher burden on 
healthcare resources. Since these disorders are potentially modi-
fiable factors, a nutritional assessment should be conducted on all 
patients on the waiting list for LT.
Criteria for diagnosing nutritional disorders have been devel-
oped by various scientific societies, but their accuracy in cases of 
advanced cirrhosis is often limited by the related changes in body 
composition. Testing for sarcopenia has emerged as the mainstay 
of nutritional assessments, however: it is objectively measure-
able and the most important nutritional variable associated with 
prognosis.
Patients awaiting LT can differ considerably in terms of their clin-
ical conditions and nutritional status. Dietary interventions should 
consequently be based on the specific needs of individual transplant 
candidates, and preferably managed by a certified nutritionist/dieti-
cian as part of a multidisciplinary approach. Any intervention should 
also include adapted physical activity and regular counselling.
Metabolic	 syndrome	 is	 very	 common	 in	 transplant	 recipients,	
and cardiovascular diseases are a major cause of long- term morbidity 
and mortality after LT. Implementing programs based on a compre-
hensive lifestyle management, a lower calorie intake, more physical 
activity and behavioural changes are believed to have a clear benefit 
in reducing this cardiovascular risk.
In Italy, as in other parts of the world, LDLT continues to be a 
small but important source of grafts to help address the shortage of 
liver donors. LDLT reduces the mortality of recipients on the waiting 
list and affords the same short- term, and better long- term allograft 
and patient survival rates than DDLT. Recipients of LDLT have more 
short- term morbidity, however, and biliary complications in particular. 
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Since donor safety remains the first priority, only a minority (around 
30%) of potential donors are acceptable candidates after a thorough 
psychosocial, medical and anatomical evaluation. The donor char-
acteristics identified as maximizing safety and efficacy for both do-
nors and recipients have include the transplant team’s experience, 
younger	donor	age,	healthy	donor	BMI,	an	adequate	remnant	volume	
of the native liver for the living donor, and accurate preoperative 
donor and recipient preparation. LDLT is now an established ther-
apy at some transplant centres in Italy, with a well- documented 40% 
perioperative donor morbidity, but also with disabling complications 
in <1% of cases, and an ongoing 0.2% risk of death. The QoL for donor 
and recipient is generally excellent. Continued advocacy is required 
to reduce social, financial and emotional roadblocks to optimal LDLT 
practice. LDLT is more challenging than DDLT because of ethical is-
sues concerning both donor and recipient. As a specialty, it therefore 
requires	full-	time	professionals	working	in	MDTs,	with	a	strong	em-
phasis on the importance of teamwork.
In the imminent future, there is likely to be a proportional 
decrease in the number or LT procedures performed because of 
ESLD. HCC will probably increasingly become the leading indica-
tion	for	LT,	and	the	time	may	be	ripe	for	an	expansion	of	the	Milan	
criteria currently used to select appropriate candidates. Expanding 
the criteria for LT in patients with HCC should not be detrimental 
to other patients with ESLD, however, and 5- year survival has to be 
adequate. A combination of morphological (tumour size and num-
ber) and biochemical (serum AFP) parameters has been proposed 
and independently validated as a broader criterion for transplant-
ing	 patients	with	HCC	 outside	 the	Milan	 criteria.	Macrovascular	
invasion or extrahepatic spread are still regarded as a contraindica-
tion to transplantation in these patients, however. When applying 
expanded criteria, it is crucially important to ensure that transplant 
centres periodically review the outcome of downstaged patients 
in order to maximize patient survival. In this regard, assessing tu-
mour aggressiveness in itinere (for example, response to downstag-
ing treatment, biochemical expression changes) should serve as a 
“test- of- time” and facilitate the choice of the best candidates for 
LT. The survival of patients who undergo downstaging treatment 
should also be expressed on an intention- to- treat basis, as this 
gives an accurate measure of the actual benefit gained by applying 
expanded criteria.
The approval of safe and effective DAAs has prompted sub-
stantial changes in the landscape of treatments for patients with 
decompensated cirrhosis, as well as for transplanted patients. 
Among several clinical and transplant- specific considerations, 
the decision to treat a decompensated patient should be bal-
anced against the risk of DAA failure in order to optimize treat-
ment strategies with a view to preventing resistance efficiently. 
Re- treatment options are limited in this setting because protease 
inhibitors are contraindicated in decompensated liver disease, and 
the safety of multiple drug combinations in compensated HCC- 
HCV is unknown. Overall, SVR is associated with a median 2- point 
reduction	 in	 MELD	 score,	 and	 a	 lower	 incidence	 of	 decompen-
sation over 12 months thereafter. Few data are available on the 
best time after the transplant to start treatment. HCV treatment 
should be started as soon as feasible, not only to optimize SVR, 
but also and especially to reduce the risk of damage to the graft. 
The rate of treatment failure with 2nd- generation DAAs in HCV 
patients after transplantation ranges between 4% and 12%. Close 
monitoring of patients’ immunosuppression levels should be rec-
ommended in view of the drug interactions between DAAs and 
calcineurin or m- TOR inhibitors.
9  | SUMMARY OF THE CONTENT
1. This position paper states that every patient potentially eligible 
for LT should be referred to a transplant hepatologist even 
for patients who ultimately do not receive a transplant.
2. Sarcopenia, obesity, and malnutrition, alone or in combination, 
are common comorbidities in liver transplant candidates and 
are associated with poor outcomes as well as a higher burden 
on healthcare resources. A nutritional assessment should be 
conducted on all patients on the waiting list for liver 
transplant.
3. In Italy, as in other parts of the world, liver donor LT continues to 
be a small but important source of grafts to help address the 
shortage of liver donors. It is more challenging than deceased 
donor liver transplant because of ethical issues concerning both 
donor and recipient.
4. In the imminent future, HCC will probably increasingly become 
the leading indication for LT, and the time may be ripe for an ex-
pansion	of	the	Milan	criteria	currently	used	to	select	appropriate	
candidates. Expanding the criteria for LT in patients with HCC 
should not be detrimental to other patients with ESLD.
5. The approval of safe and effective DAAs has prompted substan-
tial changes in the landscape of treatments for patients with de-
compensated cirrhosis, as well as for transplanted patients. Close 
monitoring of patients’ immunosuppression levels should be rec-
ommended in view of the drug interactions between some anti-
viral and some immunosuppressive drugs.
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APPENDIX 
Working Group 1
Interaction between hepatologists and transplant centres: how 
can the referral of candidates for liver transplantation be 
improved?
Coordinator:
Stefano Ginanni Corradini
Participants:
Paolo	Angeli,	Carmine	Coppola,	Nicola	De	Maria,	Flaminia	Ferri,	
Francesco	 Giuseppe	 Foschi,	 Giovanna	 Gaffuri,	 Maria	 Cristina	
Morelli,	Antonio	Ottobrelli,	Giovanni	Perricone,	Giovanni	Vizzini
Working Group 2
The “difficult candidate” for liver transplantation
Coordinator:
Pierluigi Toniutto
Participants:
Paola	Carrai,	Stefano	Fagiuoli,	Martina	Felder,	Ilaria	Lenci,	Paolo	
Pianta,	Laura	Ponti,	Alberto	Zanetto
Working Group 3
The management of nutrition before and after transplantation
Coordinator:
Paolo Caraceni
Participants:
Adele D’Antoni, Alfonso Galeota Lanza, Giacomo Germani, 
Matteo	 Angelo	 Manini,	 Manuela	 Merli,	 Maria	 Rosaria	 Piras,	
Mariarosa	Tamè.
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Working Group 4
Living donor liver transplantation (LDLT): update and perspectives
Coordinator:
Riccardo Volpes
Participants:
Luca Saverio Belli, Patrizia Burra
Working Group 5
Hepatocellular carcinoma and liver transplantation: is it time to ex-
pand the criteria in Italy?
Coordinator:
Edoardo G. Giannini
Participants:
Mario	 Angelico,	 Sherrie	 Bhoori,	 Martina	 Gambato,	 Antonio	
Grieco,	 Laura	 Mameli,	 Alfredo	 Marzano,	 Ioannis	 Petridis,	 Fabio	
Piscaglia, Francesca Romana Ponziani
Working Group 6
How to deal with direct-acting antiviral (DAA) treatment failure be-
fore and after LT
Coordinator:
Maria	Rendina
Participants:
Raffaele Bruno, Piero Colombatto, Gianpiero D’Offizi, Paolo 
Forte,	 Silvia	 Martini,	 Chiara	 Mazzarelli,	 Marzia	 Montalbano,	
Francesco Paolo Picciotto, Francesco Paolo Russo
